Achieved Revenue Growth of 106%

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today reports its financial results for the second quarter ended June 30, 2018.

Recent Highlights and Accomplishments:

  • Achieved total revenue in the second quarter 2018 of $632,000, an increase of 106%, versus the comparable period of 2017.
  • Announced agreements with leading orthotics and prosthetics (O&P) practices to bring MyoPro® availability to 16 new U.S. locations. Myomo currently has 80 U.S. locations offering the MyoPro line of powered orthosis.
  • Announced the introduction of MyoPro myoelectric arm orthosis (powered brace) for adolescent patients with paralyzed or weakened arms.
  • Received a favorable preliminary decision from the Centers for Medicare & Medicaid Services (“CMS”) regarding the Company’s application for Healthcare Common Procedure Coding System (HCPCS) “L”.
  • Appointed Micah Mitchell as Chief Commercial Officer.

Paul R. Gudonis, Chairman & CEO of Myomo, stated: “We are pleased to report quarterly revenues growth of 106% year over year. We have opened new sales regions, added new O&P locations, and launched digital marketing campaigns to reach the many individuals in the US with upper limb paralysis. With growing interest from patients and O&P providers, we continue to expect increased revenue for the year.”

Financial Results

          Three months ended Period-to-period Six months ended Period-to-period June 30, change June 30, change 2018   2017 $     % 2018   2017 $     %   Revenue $ 632,369 $ 306,683 $ 325,686 106 % $ 945,548 $ 522,914 $ 422,634 81 %   Cost of revenue 200,446   98,641   101,805 103 %   308,526   177,210   131,316 74 %   Gross margin $ 431,923 $ 208,042 $ 223,881 108 % $ 637,022 $ 345,704 $ 291,318 84 % Gross margin% 68 %   68 % - %   67 %   66 % 1 %  

Total revenue in the second quarter 2018 was $632,000, an increase of 106%, versus the comparable period of 2017. Total revenue for the six months ended June 30, 2018 was $946,000, an increase of 81%, versus the comparable period of 2017. Our results for the three and six months ended June 30, 2018, included increases in units, as well as a higher average selling price primarily due direct sales.

Gross margin was 68% for the quarter ended June 30, 2018 and 2017. Gross margin was 67% and 66% for the six months ended June 30, 2018 and 2017, respectively.

Operating expenses were $3,114,000, an increase of $973,000, or 45%, during the three months ended June 30, 2018, versus the comparable period of 2017. Operating expenses were $5,722,000, an increase of $2,079,000, or 57%, during the six months ended June 30, 2018, as compared to the six months ended June 30, 2017. The increases in our operating expenses primarily reflect higher compensation costs associated with the addition of personnel, the expansion of our sales, marketing and product development efforts, and increased spending to secure reimbursement, as well as increased administrative costs to support our growing business and public company compliance requirements.

During the three months ended June 30, 2018 the company generated interest income of $50,000, as compared to incurring interest expense of $146,250 in the same period of 2017. We did not incur interest expense during the three months ended June 30, 2018 due to the payoff of our outstanding debt and our convertible promissory notes being converted into common stock upon the closing of our IPO on June 9, 2017.

The Company’s net loss for the quarter ended June 30, 2018 amounted to $2,630,000, compared with a net loss of $7,382,000 for the corresponding period of 2017. Net loss for the quarter ended June 30, 2017 includes a $5,172,000 charge for debt discount on convertible notes. Net loss available to common stockholders for the quarter ended June 30, 2018 was $2,630,000 or ($0.21) per share, compared with a net loss available to common stockholders of $7,755,000, or ($3.35) per share, for the corresponding year ago period.

Adjusted EBITDA1 for the quarter ended June 30, 2018 was a loss of $2,512,000, compared with a loss of $1,656,000 for the corresponding 2017 period. Adjusted EBITDA for the six months ended June 30, 2018 was a loss of $4,564,000, compared with a loss of $2,997,000 for the corresponding 2017 period. A reconciliation of GAAP net loss to this non-GAAP financial measure has been provided in the financial statement tables included in this press release. An explanation of this measure is also included below under the heading “Non-GAAP Financial Measures.”

Liquidity

Cash on hand at June 30, 2018 was $11,684,000, compared to $12,959,000 at December 31, 2017.

Conference Call and Webcast InformationMyomo will hold a conference call today, August 7, 2018 at 4:30 p.m. EDT. To access the conference call, please dial 1-877-270-2148 from the U.S. or 1-412-902-6510 internationally. Please instruct the operator to join you into Myomo’s earnings conference call. A webcast and accompanying slides can also be accessed through Myomo’s Investor Relations page. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available approximately one hour after completion of the live conference call at the Investor Relations page. A dial-in replay of the call will be available until August 21, 2018; please dial 1-877-344-7529 from the U.S. or 1-412-317-0088 internationally and provide the passcode of 10122822.

(Tables follow)

About MyomoMyomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.

1 Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization adjusted for the impact of the write-off of unamortized debt discount associated with conversion of convertible notes into common stock and warrants, stock based-compensation, the impact of the fair value revaluation of our derivative liabilities and the loss on early extinguishment of debt.

Forward Looking StatementsThis press release contains forward-looking statements regarding the Company's future business expectations, including the scale-up and expansion of commercial operations, projected users of MyoPro, our expectations for revenues and our results of operations, and the potential benefits to users of our products, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

  • our sales and commercialization efforts;
  • our ability to achieve reimbursement from third-party payers for our products;
  • our dependence upon external sources for the financing of our operations;
  • our ability to effectively execute our business plan; and
  • our expectations as to our clinical research program and clinical results.

More information about these and other factors that potentially could affect our financial results is included in Myomo's filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company’s annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Non-GAAP Financial MeasuresMyomo has provided in this release of financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Myomo believes that the use of this non-GAAP financial measures provides supplementary information for investors to use in evaluating operating performance and in comparing its financial measures with other companies in Myomo’s industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for the impact of the write off of unamortized debt discount associated with conversion of convertible notes into common stock and warrants, stock based-compensation, the impact of the fair value revaluation of our derivative liabilities and the loss on early extinguishment of debt. Non-GAAP financial measures that Myomo uses may differ from measures that other companies may use. This non-GAAP financial measure disclosed by Myomo is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

 

     

MYOMO, INC.CONDENSED STATEMENTS OF OPERATIONS(unaudited)

          Three months ended

 

Six months ended

June 30,

 

June 30,

2018     2017 2018     2017 Revenue $ 632,369 $ 306,683 945,548 $ 522,914   Cost of revenue   200,446   98,641 308,526   177,210   Gross margin   431,923   208,042 637,022   345,704   Operating expenses: Research and development 486,982 708,622 859,341 1,065,507 Selling, general and administrative   2,627,005   1,432,862 4,862,642   2,577,328   Total operating expenses   3,113,987   2,141,484 5,721,983   3,642,835   Loss from operations (2,682,064) (1,933,442) (5,084,961) (3,297,131)   Other expense (income) Change in fair value of derivative liabilities (2,661) 130,162 (17,968) 155,008 Debt discount on convertible notes — 5,172,000 — 5,172,000 Interest and other expense, net   (49,842)   146,250 (92,030)   314,115 Total other expense (income)   (52,503)   5,448,412 (109,998)   5,641,123     Net loss (2,629,561) (7,381,854) (4,974,963) (8,938,254) Deemed discount – accreted preferred stock discount — (246,827) — (274,011) Cumulative dividend to Series B-1 preferred stockholders —   (125,903) —   (287,779) Net loss available to common stockholders $ (2,629,561) $ (7,754,584) (4,974,963) $ (9,500,044)   Weighted average number of common shares outstanding: Basic and diluted   12,407,526   2,312,649 12,155,600   1,722,168   Net loss per share available to common stockholders: Basic and diluted $ (0.21) $ (3.35) (0.41) $ (5.52)         MYOMO, INC. CONDENSED BALANCE SHEETS   June 30, 2018 December 31, 2017 ASSETS (Unaudited) Current Assets: Cash and cash equivalents $ 11,683,729 $ 12,959,373 Accounts receivable 384,951 297,039 Inventories, net 247,624 201,155 Prepaid expenses and other 462,782     388,275   Total Current Assets 12,779,086 13,845,842 Restricted cash 75,000 52,000 Deferred offering costs 49,042 — Equipment, net 163,849     77,150   Total Assets $ 13,066,977   $ 13,974,992     LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) Current liabilities: Accounts payable and other accrued expenses $ 1,399,335 $ 1,277,236 Derivative liabilities 21,962 39,930 Deferred revenue 149,086   168,006   Total Current Liabilities 1,570,383 1,485,172 Deferred revenue, net of current portion 45,496   44,042   Total Liabilities 1,615,879     1,529,214     Commitments and Contingencies — —   Stockholders' Equity (Deficiency) Common stock 1,241 1,114 Undesignated preferred stock — — Additional paid-in capital 51,404,071 47,423,915 Accumulated deficit (39,947,750 ) (34,972,787 ) Treasury stock (6,464 )   (6,464 ) Total Stockholders' Equity (Deficiency) 11,451,098     12,445,778   Total Liabilities and Stockholders’ Equity (Deficiency) $ 13,066,977   $ 13,974,992          

MYOMO, INC.CONDENSED STATEMENTS OF CASH FLOWS(unaudited)

  For the six months ended June 30, 2018 2017 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (4,974,963 ) $ (8,938,254 ) Adjustments to reconcile net loss to net cash used in operations: Depreciation 28,900 4,546 Stock-based compensation 492,080 295,418 Amortization of debt discount — 17,765 Debt discount on convertible notes — 5,172,000 Excess and obsolete inventory reserve 28,887 36,028 Common stock issued for services — 30,000 Change in fair value of derivative liabilities (17,968 ) 155,008 Changes in operating assets and liabilities: Accounts receivable (87,912 ) (139,525 ) Inventories (109,498 ) (76,621 ) Prepaid expenses and other (74,507 ) (121,633 ) Accounts payable and other accrued expenses 122,099 594,339 Accrued interest — 209,627 Deferred revenue (17,466 ) 14,297   Net cash used in operating activities (4,610,348 ) (2,747,005 ) CASH FLOWS FROM INVESTING ACTIVITIES Purchases of equipment (81,457 ) (4,987 ) Net cash used in investing activities (81,457 ) (4,987 ) CASH FLOWS FROM FINANCING ACTIVITIES Payments of issuance costs (49,042 ) — Net settlement of vested restricted stock units to fund relatedemployee statutory tax withholding (68,190 ) — Proceeds from exercise of stock options 2 2,982 Proceeds from exercise of warrants 3,556,391 — Proceeds from IPO, net of offering costs (1) — 4,423,315 Proceeds from private placement, net of offering costs — 2,922,885 Proceeds from convertible promissory notes, net — 1,770,000 Repayment of note payable, MLSC —   (54,123 ) Net cash provided by financing activities 3,439,161   9,065,059     Net (decrease) increase in cash, cash equivalents and restricted cash (1,252,644 ) 6,313,067   Cash, cash equivalents and restricted cash, beginning of period 13,011,373   849,174       Cash, cash equivalents and restricted cash, end of period $ 11,758,729   $ 7,162,241     SUPPLEMENTAL DISCLOSURE CASH FLOW INFORMATION Cash paid during the period for interest $ — $ 59,536   SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTINGAND FINANCING ACTIVITIES Inventory capitalized as sales demo equipment $ 34,142 $ — Exchange of 2015 convertible promissory notes for 2016convertible promissory notes $ — $ 430,000 Accretion of convertible preferred stock to redemption value $ — $ 274,011 Conversion of accrued interest to principal $ — $ 21,916 Conversion of convertible preferred stock into common stock $ — $ 12,946,252 Conversion of convertible promissory notes and accrued interestinto common stock $ — $ 5,467,389 Issuance of selling agent warrants in connection with IPO $ — $ 156,725 Deferred offering costs to additional paid-in capital upon IPO closing (1) $ — $ 438,237 IPO issuance costs included in accounts payable and accrued expense $ — $ 31,930    

 

(1) IPO gross proceeds of $4,991,236 are reduced by $567,921 of IPO offering costs that were incurred in 2017. Another $438,237 of IPO deferred offering costs were paid for in 2016.

 

   

MYOMO, INC.RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

   

(unaudited)

          Three months ended Six months ended June 30, June 30, 2018 2017 2018 2017 GAAP net loss $ (2,629,561) $ (7,381,854) $ (4,974,963) $ (8,938,254) Adjustments to reconcile to Adjusted EBITDA:   Interest (income) expense (49,842) 146,057 (92,030) 286,928 Other expense — 193 — 27,187 Depreciation expense 14,301 2,377 28,900 4,546 Stock-based compensation 155,724 275,279 492,080 295,418 Change in fair value of derivative liabilities (2,661) 130,162 (17,968) 155,008 Debt discount on convertible notes   —   5,172,000   —   5,172,000 Adjusted EBITDA $ (2,512,039) $ (1,655,786) $ (4,563,981) $ (2,997,167)

For Myomo:ir@myomo.comorInvestor Relations:PCG AdvisoryVivian Cervantes, 646-863-6274vivian@pcgadvisory.comorPublic Relations:GreenoughRachel Robbins, 617-275-6521rrobbins@greenough.biz

Myomo (AMEX:MYO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Myomo Charts.
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Myomo Charts.